Patients with RA and RARS who have a higher percentage of BMI-1+ cells showed disease progression to RAEB, suggesting that BMI-1 is a novel molecular marker that predicts the progression and prognosis of MDS [28]. This evidence concerns the gene BMI1 and myelodysplastic syndrome.